Almac Adds Simple Solutions to Bridge the Gap Between Clinical and Commercial Packaging
Addressing client demand to ease the transition between clinical and commercial launch for blister products...
Addressing client demand to ease the transition between clinical and commercial launch for blister products, Almac, provider in clinical and commercial contract packaging to the global Pharmaceutical and Biotech industries, has added new blistering technology at their US commercial packaging facility in Audubon, PA
The Klockner EAS blister line can produce a range of blister formats processing both thermoform and coldform materials. This provides simple solutions for client packaging projects requiring low volume runs for evaluation of different packaging material combinations and cost effective stability packaging.
David Moore, Director of Operations at the Audubon facility explains “Almac are offering seamless services from clinical supply, packaging development / design and stability testing to final commercial pack from its two Pennsylvania sites. Clients can now easily transition from the clinical blister presentation though various development packs, with Almac providing all the associated stability services.”
The addition of a further blister line complements the already impressive array of clinical and commercial packaging capabilities of blistering, bottling, walleting and vial /ampoule labelling available at Almac.
For more information on Almac’s US packaging capabilities, please contact
[email protected]
Almac will be exhibiting at Pharma Packaging & Labeling Philadelphia 26 – 27 Feb 2014 and Interphex New York 18 – 20 March 2014.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
